Using a pharmacokinetics-based approach, we were able to predict the effects of age on numerous drugs that undergo similar pathways of elimination to optimize pediatric doses when specific pharmacokinetic data are limited or unavailable. In general, for many new drugs, substantially more premarketing pharmacokinetic information is available for adults than for children. This information can be useful for predicting pediatric doses when other data are limited or missing. We hope that the need for this mechanistic approach to estimating pediatric doses will be diminished in the future, as more drugs are being evaluated in infants and children during initial development.
Pharmacotherapy. 2009;29(6):680-690. © 2009
Cite this: Optimizing Pediatric Dosing: A Developmental Pharmacologic Approach - Medscape - Jun 01, 2009.